• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Yumanity Therapeutics Inc.

    2/14/23 9:15:52 AM ET
    $YMTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $YMTX alert in real time by email
    SC 13G 1 d465720dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No.     )*

     

     

    Kineta, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    49461C 102

    (CUSIP Number)

    December 16, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 49461C 102    13G    Page 2 of 9 Pages

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      CBI USA, Inc.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      656,941

       6  

      SHARED VOTING POWER

     

      0

       7  

      SOLE DISPOSITIVE POWER

     

      656,941

       8  

      SHARED DISPOSITIVE POWER

     

      0

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      656,941

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      7.9%

    12  

      TYPE OF REPORTING PERSON

     

      OO

     

    Page 2 of 9


    CUSIP No. 49461C 102    13G    Page 3 of 9 Pages

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      CBI Co. Ltd.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Republic of Korea

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      721,111

       6  

      SHARED VOTING POWER

     

      0

       7  

      SOLE DISPOSITIVE POWER

     

      721,111

       8  

      SHARED DISPOSITIVE POWER

     

      0

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      721,111

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      8.6%

    12  

      TYPE OF REPORTING PERSON

     

      OO

     

    Page 3 of 9


    CUSIP No. 49461C 102    13G    Page 4 of 9 Pages

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Daehan Green Power Corporation

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Republic of Korea

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      100,409

       6  

      SHARED VOTING POWER

     

      0

       7  

      SOLE DISPOSITIVE POWER

     

      100,409

       8  

      SHARED DISPOSITIVE POWER

     

      0

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      100,409

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      1.2%

    12  

      TYPE OF REPORTING PERSON

     

      OO

     

    Page 4 of 9


    Item 1(a).

    Name of Issuer:

    Kineta, Inc. (the “Issuer”)

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    219 Terry Ave. N., Suite 300, Seattle, WA 98109

     

    Item 2(a).

    Name of Person Filing

     

    Item 2(b).

    Address of Principal Business Office or, if none, Residence:

     

    Item 2(c).

    Citizenship

    This Statement on Schedule 13G is jointly filed by CBI USA, Inc. (“CBI USA”), CBI Co. Ltd. (“CBI Co”) and Daehan Green Power Corporation (“DGP”) (each a “Reporting Person” and, collectively, the “Reporting Persons”). CBI USA is a subsidiary of CBI Co.

    The address of CBI USA is 3000 Western Avenue, Suite 400, Seattle, WA 98121. CBI USA is a Delaware corporation.

    The address of CBI Co is 208, namdong-daero, namdong-gu, Incheon, Republic of Korea (21643). CBI Co is a Republic of Korea listed company.

    The address of DGP is 23, Geurintekeu-ro, Yeonggwang-eup, Yeonggwang-gun, Jeollanam-do, Republic of Korea (57024). DGP is a Republic of Korea listed company.

     

    Item 2(d).

    Title of Class of Securities:

    Common Stock, par value $0.001 per share (“Common Stock”)

     

    Item 2(e).

    CUSIP Number:

    49461C 102

     

    Item 3.

    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      ☒    Not applicable.
    (a)   ☐    Broker or dealer registered under Section 15 of the Exchange Act.
    (b)   ☐    Bank as defined in Section 3(a)(6) of the Exchange Act.
    (c)   ☐    Insurance company as defined in Section 3(a)(19) of the Exchange Act.
    (d)   ☐    Investment company registered under Section 8 of the Investment Company Act.
    (e)   ☐    An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
    (f)   ☐    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).

     

    Page 5 of 9


    (g)   ☐    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
    (h)   ☐    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
    (i)   ☐    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
    (j)   ☐    A non-U.S. institution, in accordance with Rule 13d-1(b)(1)(ii)(J).
    (k)   ☐    Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

    Item 4.

    Ownership.

     

      (a)

    As of the close of business on December 16, 2022:

    CBI USA beneficially owns 656,941 shares of Common Stock, consisting of 618,214 outstanding shares directly held, plus an additional 38,727 shares that may be acquired pursuant to warrants that are exercisable within 60 days.

    CBI Co is deemed to beneficially own 721,111 shares of Common Stock, consisting of the shares of Common Stock directly held or acquirable by CBI USA, its subsidiary, as described in the preceding paragraph, plus 55,871 outstanding shares directly held and an additional 8,299 shares that may be acquired pursuant to warrants that are exercisable within 60 days.

    DGP beneficially owned 100,409 shares of Common Stock, consisting of 86,580 outstanding shares directly held, plus an additional 13,829 shares that may be acquired pursuant to warrants that are exercisable within 60 days.

    CBI Co and DGP have overlapping board members, and the Chief Executive Officer of DGP is also the Chief Executive Officer of CBI USA and CBI Co. As a result of these relationships, the Reporting Persons may be deemed to be a group for purposes of Section 13(d) under the Securities Exchange Act of 1934.

    Except as set forth above, each Reporting Person disclaims beneficial ownership of the shares of Common Stock held by any person other than such reporting Person.

     

      (b)

    Percent of Class:

    As of the close of business on December 16, 2022, (i) CBI USA beneficially owns 7.9% of the outstanding shares of Common Stock, (ii) CBI Co. beneficially owns 8.6% of the outstanding shares of Common Stock (which is inclusive of the beneficial ownership of CBI USA) and (iii) DGP beneficially owns 1.2% of the outstanding shares of Common Stock.

    The percentage is calculated based upon 8,317,798 shares of Common Stock outstanding as reported in the Issuer’s Form S-3, filed with the SEC on January 20, 2023 (plus the number of shares of Common Stock acquirable pursuant to warrants to the extent such shares are included in beneficial ownership of a such person).

     

      (c)

    Number of shares as to which such person has:

     

    Page 6 of 9


      (i)

    sole power to vote or to direct the vote:

    See Cover Pages Items 5-9.

     

      (ii)

    shared power to vote or to direct the vote:

    See Cover Pages Items 5-9.

     

      (iii)

    sole power to dispose or to direct the disposition of:

    See Cover Pages Items 5-9.

     

      (iv)

    shared power to dispose or to direct the disposition of:

    See Cover Pages Items 5-9.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    Not applicable.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    See Item 4(a) and Exhibit 99.1.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certification.

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Page 7 of 9


    SIGNATURE

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: February 14, 2023

     

    CBI USA, Inc.
    By:  

    /s/ Kyungwon Oh

    Name:   Kyungwon Oh
    Title:   Chief Executive Officer
    CBI Co. Ltd.
    By:  

    /s/ Kyungwon Oh

    Name:   Kyungwon Oh
    Title:   Chief Executive Officer
    Daehan Green Power Corporation
    By:  

    /s/ Kyungwon Oh

    Name:   Kyungwon Oh
    Title:   Chief Executive Officer

     

    Page 8 of 9

    Get the next $YMTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $YMTX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $YMTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on Yumanity Therapeutics with a new price target

      HC Wainwright & Co. initiated coverage of Yumanity Therapeutics with a rating of Buy and set a new price target of $39.00

      6/4/21 6:11:47 AM ET
      $YMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Yumanity Therapeutics with a new price target

      Jefferies initiated coverage of Yumanity Therapeutics with a rating of Buy and set a new price target of $35.00

      4/1/21 9:59:39 AM ET
      $YMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $YMTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Yumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with Kineta

      Special dividend estimated to be in range of $1.34 to $1.43 per share Payment of special dividend conditioned upon closing of both Asset Sale and Merger, which are subject to stockholder approval BOSTON, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. ("Yumanity" or the "Company") (NASDAQ:YMTX) announced today that its Board of Directors has declared a special dividend in connection with the previously announced asset sale to Janssen Pharmaceutica NV ("Janssen") and merger with Kineta, Inc. ("Kineta"). The special dividend, which the Company estimates will be in range of $1.34 to $1.43 per share of Yumanity common stock, will be payable in cash on or before December 29, 20

      12/5/22 7:30:00 AM ET
      $YMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

      BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. ("Yumanity" or the "Company") (NASDAQ:YMTX), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2022 and provided an overview of the Company's recent corporate developments. Recent Corporate Developments On November 10, 2022, Yumanity announced the effectiveness of a registration statement on Form S-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission (the "SEC") in connection with Yumanity's previously announced proposed sale of Yumanity's lead clinical-stage product candidate, YTX-7739, as well as Yumanit

      11/14/22 8:16:25 AM ET
      $YMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Yumanity Therapeutics Announces Effectiveness of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta, Inc.

      BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. ("Yumanity" or the "Company") (NASDAQ:YMTX) today announced that the registration statement on Form S-4 (the "Registration Statement"), relating to the previously announced asset sale to Janssen Pharmaceutica NV ("Janssen") and merger with Kineta, Inc. ("Kineta"), has been declared effective by the U.S. Securities and Exchange Commission. In June 2022, the Company announced definitive agreements for two strategic transactions. The first definitive agreement is an asset purchase agreement for the sale of Yumanity's lead clinical-stage product candidate, YTX-7739, as well as Yumanity's unpartnered discovery-stage neurosci

      11/10/22 4:15:00 PM ET
      $YMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $YMTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Yumanity Therapeutics Inc.

      SC 13G - KINETA, INC./DE (0001445283) (Subject)

      2/14/24 3:40:31 PM ET
      $YMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Yumanity Therapeutics Inc. (Amendment)

      SC 13D/A - KINETA, INC./DE (0001445283) (Subject)

      2/12/24 4:05:45 PM ET
      $YMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Yumanity Therapeutics Inc. (Amendment)

      SC 13G/A - KINETA, INC./DE (0001445283) (Subject)

      2/12/24 4:05:16 PM ET
      $YMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $YMTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Bartoszek Raymond J. bought $9,950 worth of shares (2,250 units at $4.42), increasing direct ownership by 15% to 17,206 units (SEC Form 4)

      4 - KINETA, INC./DE (0001445283) (Issuer)

      12/6/23 6:21:27 PM ET
      $YMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Philips Craig W. bought $9,812 worth of shares (3,000 units at $3.27), increasing direct ownership by 5% to 60,811 units (SEC Form 4)

      4 - KINETA, INC./DE (0001445283) (Issuer)

      11/30/23 5:27:11 PM ET
      $YMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iadonato Shawn bought $17,398 worth of shares (5,000 units at $3.48), increasing direct ownership by 0.75% to 675,230 units (SEC Form 4)

      4 - KINETA, INC./DE (0001445283) (Issuer)

      11/30/23 5:21:22 PM ET
      $YMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $YMTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Yumanity Therapeutics Appoints Michael D. Wyzga as Chief Financial Officer and Announces Inducement Grants

      BOSTON, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ:YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced the appointment of Michael D. Wyzga as Senior Vice President, Chief Financial Officer. "Michael's financial expertise combined with his proven ability to execute strategic and operational objectives will be invaluable to the Company," said Richard Peters, M.D., Ph.D., President, Chief Executive Officer and Director of Yumanity Therapeutics. "We are looking forward to Michael's contributions as we continue to pursue our vision of a future f

      8/16/21 7:00:00 AM ET
      $YMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Yumanity Therapeutics Appoints Devin W. Smith as General Counsel

      BOSTON, June 14, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ:YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced the appointment of Devin W. Smith as Senior Vice President and General Counsel. "We are delighted to welcome Devin as our general counsel at Yumanity Therapeutics," said Richard Peters, M.D., Ph.D., President, Chief Executive Officer and Director of Yumanity Therapeutics. "His experience providing legal counsel to public emerging life science companies will be important as we advance three clinical programs, move new innovative assets to t

      6/14/21 7:00:00 AM ET
      $YMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Yumanity Therapeutics Appoints Neuroscience Drug Development Veteran, Ajay Verma, M.D., Ph.D., Executive Vice President, Head of Research & Development

      BOSTON, April 13, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ:YMTX), a biopharmaceutical company focused on the development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced the appointment of Ajay Verma, M.D., Ph.D., as Executive Vice President, Head of Research & Development. Dr. Verma brings more than 25 years of experience developing biotherapeutics in the field of neuroscience. "We are delighted to welcome Dr. Ajay Verma in the newly-created role of Head of R&D at Yumanity Therapeutics," said Richard Peters, M.D., Ph.D., President, Chief Executive Officer and Director of Yumanity Therapeutics. "As a clinically trained neurologist, A

      4/13/21 8:00:00 AM ET
      $YMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $YMTX
    SEC Filings

    See more
    • Yumanity Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - KINETA, INC./DE (0001445283) (Filer)

      1/17/24 8:30:09 AM ET
      $YMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Yumanity Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - KINETA, INC./DE (0001445283) (Filer)

      1/5/24 4:30:28 PM ET
      $YMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Yumanity Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - KINETA, INC./DE (0001445283) (Filer)

      12/15/23 8:30:30 AM ET
      $YMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $YMTX
    Financials

    Live finance-specific insights

    See more
    • Yumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with Kineta

      Special dividend estimated to be in range of $1.34 to $1.43 per share Payment of special dividend conditioned upon closing of both Asset Sale and Merger, which are subject to stockholder approval BOSTON, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. ("Yumanity" or the "Company") (NASDAQ:YMTX) announced today that its Board of Directors has declared a special dividend in connection with the previously announced asset sale to Janssen Pharmaceutica NV ("Janssen") and merger with Kineta, Inc. ("Kineta"). The special dividend, which the Company estimates will be in range of $1.34 to $1.43 per share of Yumanity common stock, will be payable in cash on or before December 29, 20

      12/5/22 7:30:00 AM ET
      $YMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

      BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. ("Yumanity" or the "Company") (NASDAQ:YMTX), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2022 and provided an overview of the Company's recent corporate developments. Recent Corporate Developments On November 10, 2022, Yumanity announced the effectiveness of a registration statement on Form S-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission (the "SEC") in connection with Yumanity's previously announced proposed sale of Yumanity's lead clinical-stage product candidate, YTX-7739, as well as Yumanit

      11/14/22 8:16:25 AM ET
      $YMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Yumanity Therapeutics Announces Effectiveness of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta, Inc.

      BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. ("Yumanity" or the "Company") (NASDAQ:YMTX) today announced that the registration statement on Form S-4 (the "Registration Statement"), relating to the previously announced asset sale to Janssen Pharmaceutica NV ("Janssen") and merger with Kineta, Inc. ("Kineta"), has been declared effective by the U.S. Securities and Exchange Commission. In June 2022, the Company announced definitive agreements for two strategic transactions. The first definitive agreement is an asset purchase agreement for the sale of Yumanity's lead clinical-stage product candidate, YTX-7739, as well as Yumanity's unpartnered discovery-stage neurosci

      11/10/22 4:15:00 PM ET
      $YMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $YMTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Bartoszek Raymond J. bought $9,950 worth of shares (2,250 units at $4.42), increasing direct ownership by 15% to 17,206 units (SEC Form 4)

      4 - KINETA, INC./DE (0001445283) (Issuer)

      12/6/23 6:21:27 PM ET
      $YMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Philips Craig W. bought $9,812 worth of shares (3,000 units at $3.27), increasing direct ownership by 5% to 60,811 units (SEC Form 4)

      4 - KINETA, INC./DE (0001445283) (Issuer)

      11/30/23 5:27:11 PM ET
      $YMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iadonato Shawn bought $17,398 worth of shares (5,000 units at $3.48), increasing direct ownership by 0.75% to 675,230 units (SEC Form 4)

      4 - KINETA, INC./DE (0001445283) (Issuer)

      11/30/23 5:21:22 PM ET
      $YMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care